The NOV gene product, CCN3, has been reported in a diverse range of tumors to serve as a negative growth regulator, while acting as a tumor suppressor in Chronic Myelogenous Leukemia (CML). Here, CCN3 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.